Notice for emicizumab (Roche Products Pty Limited)
Active ingredients
emicizumab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Emicizumab is indicated for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors.